What Novogene does

Novogene is a China-headquartered, publicly listed (Shanghai STAR market, ticker NGE) genomics sequencing services company founded in 2011 by Ruiqiang Li. It operates a global network of certified laboratories across China, the US (Sacramento and Beaverton), the UK (Cambridge), Germany (Munich), the Netherlands, Singapore, Japan, Korea, and Thailand, serving customers in 73+ countries. Its core offering is fee-for-service next-generation sequencing across the full multi-omics stack: genome, transcriptome, epigenome, metagenome, single-cell, spatial, proteomic, and metabolomic services, delivered on multiple certified sequencing platforms including Illumina, Pacific Biosciences, Oxford Nanopore Technologies, Ultima Genomics, and 10x Genomics.

The technology stack centers on the FALCON platform — described by the company as the first fully automated intelligent delivery system in the NGS industry — supplemented by the NovoMagic online RNA-seq bioinformatics tool and a Customer Service System (CSS) for project tracking. Clinical-grade services are delivered under CLIA and CAP certifications, including clinical whole exome sequencing and clinical panels for healthcare providers. Revenue is generated on a per-sample or per-project basis with published unit pricing (e.g., from $1,999 per 10x Single Cell RNA-seq sample and $3,399 per Ultima wafer for 10 billion reads), complemented by quote-based enterprise pricing for larger research programs.

The go-to-market is direct enterprise field sales targeting research institutions, universities, hospitals, pharmaceutical and biotechnology companies, and agrigenomics customers, supported by content marketing, scientific publications, and regional event participation. The company's growth strategy combines menu expansion (multiple 2025 launches across spatial, single-cell, and proteomics), geographic buildout (e.g., Korea subsidiary established June 2025), and partnership-led entry into large-scale programs such as the PRECISE-SG100K Singapore biobank. The business faces a material regulatory overhang from the June 8, 2026 U.S. Department of Defense designation of Novogene Co., Ltd. on the Section 1260H list of alleged Chinese military companies, which the company publicly disputes as erroneous and which carries downstream BIOSECURE Act procurement implications.

Name

Novogene

Legal name

Novogene Corporation Inc.

Website

https://en.novogene.com

Company type

Public

Founded year

2011

Operating status

Operating

Headcount range

251–500 employees

Short description

Novogene is a Shanghai STAR-listed (NGE) global genomics services company offering NGS-based multi-omics sequencing (genomics, transcriptomics, epigenomics, proteomics, metabolomics) on Illumina, PacBio, ONT, and 10x platforms for research institutions, hospitals, pharma, and agrigenomics customers across 73+ countries.

Ownership category

akta.pro rank

Product category

Genomics Sequencing Services

NAICS

Scientific Research and Development Services (5417), Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

In Vitro & In Vivo Diagnostic Substances (2835)

akta.pro primary industry

Genomics & Next-Generation Sequencing (NGS) Services (HLAGANAA)

akta.pro secondary industries

Transcriptomics & Gene Expression Profiling Services (HLAGANAE), Genomic & Multi-Omic Biomarkers (NGS panels, transcriptomics, proteomics, metabolomics) (HLAAAMAJ), Molecular Diagnostics & Genomics Laboratories (HLAFAMAE), Genomics & Molecular Diagnostics (Trial Support) (HLAGAEAD)

Keywords

• Next-generation sequencing
• Multi-omics services
• Clinical genomics
• Bioinformatics analysis
• Genomic sequencing

Headquarters

HQ city

Beijing

HQ country

China

HQ region

Asia

Offices10 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Technology or R&D, Infrastructure, Marketing or Sales, Supply Chain

Revenue model

1. NGS Laboratory Services: Fee-for-service laboratory testing model where customers submit biological samples for sequencing and analysis. Services include genome sequencing, transcriptome sequencing, single-cell sequencing, epigenomics, proteomics and metabolomics. Revenue is generated on a per-sample or per-project basis with pricing based on sequencing depth, sample type, and turnaround time requirements.
2. Clinical Diagnostics Services: Clinical-grade sequencing services including Clinical Whole Exome Sequencing (CLIA/CAP compliant) and clinical panels for healthcare providers.

Pricing tiers

Go-to-market motion1 record

Distribution channels2 records

Marketing channels5 records

Core offering

Novogene is a global provider of next-generation sequencing (NGS) services and multi-omics solutions, operating certified laboratories that perform genomic, transcriptomic, epigenomic, proteomic, and metabolomic analyses for research institutions, universities, pharmaceutical companies, and healthcare providers. The company delivers fee-for-service sequencing across multiple platforms (Illumina, Pacific Biosciences, Oxford Nanopore Technologies, Ultima Genomics) with integrated bioinformatics analysis, supported by the proprietary FALCON automated delivery platform.

Product overview

Novogene is a genomics services company offering a comprehensive portfolio of next-generation sequencing (NGS) services organized around core service categories: Genome Sequencing (including whole genome, exome, and de novo sequencing for human, animal, plant, and microbial samples), Transcriptome Sequencing (mRNA, non-coding RNA, small RNA, circular RNA, and isoform sequencing), Single Cell Sequencing (10x Genomics and Illumina Pip-Seq platforms with spatial transcriptomics), Epigenome Sequencing (methylation, ChIP-seq, ATAC-seq), Metagenome Sequencing (16S/18S/ITS amplicon and shotgun metagenomics), Proteomics & Metabolomics (untargeted metabolomics, lipidomics, Olink proteomics, quantitative proteomics), and Clinical Diagnostics (CLIA/CAP certified whole exome and clinical panels). These services are supported by the FALCON intelligent delivery platform for automated sample processing, NovoMagic bioinformatics analysis tools, and a Customer Service System (CSS) for project management. The company operates certified labs in the USA (California, Oregon), UK, Singapore, Japan, Korea, Germany, Netherlands, and China, utilizing sequencing platforms from Illumina, Pacific Biosciences, Oxford Nanopore Technologies, and Ultima Genomics.

Differentiator

Problem solved

Functional benefit

Products and services

• Genome Sequencing Services Comprehensive genome sequencing services for human, animal, plant, and microbial samples, including Human Whole Genome Sequencing, Human/Mouse Whole Exome Sequencing, Animal and Plant De novo Sequencing, and Microbial Whole Genome Sequencing. Targeted at research institutions and pharmaceutical companies.
• Metagenome Sequencing Services Metagenomic sequencing including 16S/18S/ITS Amplicon Metagenomic Sequencing and Shotgun Metagenomic Sequencing for microbiome analysis across human, environmental, and food science applications.
• Transcriptome Sequencing Services Comprehensive transcriptome analysis including mRNA Sequencing, lncRNA-seq, Small RNA Sequencing, Circular RNA Sequencing, Whole Transcriptome Sequencing, Isoform Sequencing (ISO-seq), Prokaryotic RNA Sequencing, and Metatranscriptome Sequencing.
• Single Cell Sequencing Services Single-cell analysis services utilizing 10x Genomics and Illumina Pip-Seq platforms, including 10x Single Cell RNA-seq, Illumina Pip-Seq Single Cell 3' RNA Sequencing, and Spatial Transcriptome Sequencing for high-resolution cellular analysis.
• Epigenome Sequencing Services Epigenetic analysis services including Whole Genome Bisulfite Sequencing (WGBS), Direct Methylation Sequencing (DM-Seq), Reduced Representation Bisulfite Sequencing (RRBS), ChIP-seq, RIP-seq, ATAC-seq, and Enzymatic Methyl Sequencing.
• Proteomics and Metabolomics Services Protein and metabolite profiling services including Untargeted Metabolomics, Quantitative Lipidomics, Widely-Targeted Metabolomics, Olink Reveal Proteomics, and Quantitative Proteomics powered by the Orbitrap Astral platform.
• Pre-made Library Sequencing
• Clinical Whole Exome Sequencing (CLIA/CAP) Clinical-grade whole exome sequencing service with CLIA and CAP certification for diagnostic applications, supporting rare and complex disease research and clinical testing for healthcare providers and hospitals.
• Clinical Panels Targeted clinical sequencing panels for specific disease areas and diagnostic applications, provided under CLIA/CAP clinical laboratory certifications for healthcare providers.
• FALCON Intelligent Delivery Platform The first fully automated, intelligent delivery system in the NGS industry, launched in 2020. Provides highly efficient, reliable, and flexible sample processing and data delivery for sequencing services customers.
• NovoMagic Bioinformatics Analysis Tool Online bioinformatics analysis platform for RNA-seq data interpretation, providing researchers with tools for data analysis and visualization.
• Customer Service System (CSS) Project management and customer service platform enabling clients to track samples, access results, and manage sequencing projects throughout the service lifecycle.

Quantifiable outcome

• Data delivery in as little as 5 business days for mRNA sequencing
• +1 more outcomes

Named customers3 records

Segments4 records

Ideal customer profiles4 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Integration6 records

Feature5 records

Partnerships

Five partnerships are on record, tiered core.

• Precision Health Research, Singapore (PRECISE)coreStrategic or Co-development Partner · 9 April 2026Thermo Fisher Scientific announced a strategic collaboration with PRECISE for the PRECISE-SG100K population-scale biobank initiative. Novogene is integrated into this collaboration as a partner for genomic sequencing services, contributing to the integration of data with global biobank efforts.
• Oxford Nanopore Technologies (ONT)coreTechnology or Integration · 5 November 2025Novogene Europe launched a Whole Plasmid Sequencing service powered by Oxford Nanopore Technologies (ONT). The service provides complete coverage for plasmids with fast turnaround, high-quality data, and flexible throughput options for applications in gene and cell therapy, RNA therapeutics, and synthetic biology.
• 10x GenomicscoreTechnology or IntegrationNovogene offers single-cell sequencing services using 10x Genomics platforms, including 10x Single Cell RNA-seq and 10x Visium HD spatial transcriptomics. The company is certified by 10x Genomics for these services.
• IlluminacoreTechnology or IntegrationNovogene operates Illumina-certified laboratories and offers a wide range of sequencing services on Illumina platforms including NovaSeq, NextSeq, and MiSeq systems for various applications from whole genome to targeted sequencing.
• Pacific Biosciences (PacBio)coreTechnology or IntegrationNovogene provides long-read sequencing services using Pacific Biosciences platforms for applications requiring extended read lengths, including de novo sequencing and complex structural variant analysis.

Scale indicators3 records

Recent moves7 records

Expansion highlights5 records

Emerging players

• Element Biosciences: Emerging NGS instrument vendor (AVITI platform) increasingly used by independent service labs; an emerging threat to incumbent service labs like Novogene that are tied to Illumina/PacBio platforms.

Broad incumbents

• Illumina: Dominant NGS instrument and reagent vendor; also offers its own CLIA-certified clinical sequencing services (e.g., TruSight, Illumina Connected Insights), making it both a key supplier and a broad competitor across the value chain.
• Thermo Fisher Scientific: Provides genomic services through PPD and its specialty diagnostics/CDMO arms; competes with Novogene for pharma clinical trial genomics and biopharma services while also supplying it with instruments and reagents.
• QIAGEN: Global molecular diagnostics and sample-prep provider with NGS-targeted bioinformatics (QIAGEN Digital Insights) and clinical genomics offerings; competes with Novogene's clinical and bioinformatics services.

Direct peers

• Azenta Life Sciences (GENEWIZ): Global genomics services provider (formerly GENEWIZ) offering Sanger, NGS, and synthetic biology services; competes directly with Novogene in US and European research customer accounts.
• CD Genomics: US-based NGS services provider offering whole genome, exome, RNA-seq, single-cell, and microbiome sequencing to research and pharma customers; closely comparable mid-tier peer to Novogene's US sequencing business.
• Eurofins Genomics: One of the largest global providers of genomic services (sequencing, genotyping, oligo synthesis) with deep European and US footprint; competes directly with Novogene for research institution and pharma customers.
• Macrogen: Korean-headquartered global genomics services company offering NGS, microarray, and clinical sequencing; competes with Novogene especially across APAC and on CLIA-certified clinical sequencing projects.
• BGI Genomics: Largest Chinese genomics services company, publicly listed, offering global NGS and multi-omics services directly competing with Novogene across research and clinical customers; was also added to the Pentagon 1260H list alongside Novogene.

Regional players

• MGI Tech (BGI subsidiary): BGI-affiliated sequencing platform vendor (DNBSEQ) primarily serving APAC markets; competes with Novogene in Asia and represents an alternative platform ecosystem to the Illumina/PacBio/ONT stack Novogene relies on.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xx.com/novogene_us
• YouTubeyoutube.com/c/NovogeneGlobal
• Facebookfacebook.com/NovogeneAmerica
• LinkedInlinkedin.com/company/novogene-corporation
• Instagraminstagram.com/novogeneamerica

Compliance2 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Subsidiaries10 records

Funding overview

Funding rounds1 record

Investors4 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Novogene